Novo Nordisk faces sustained margin compression due to intensifying price competition in the GLP-1 weight loss drug market.

April 28 (Reuters) - Health Canada has approved the first generic version of Danish drugmaker Novo Nordisk's blockbuster diabetes drug Ozempic made by Indian drugmaker Dr Reddy's Laboratories, its ...

The drugmaker is getting on the AI train in ways that could move the needle down the road.

Novo Nordisk (CPSE:NOVO B) has received U.S. FDA Fast Track Designation for coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy. The company also reported successful pivotal Phase 3 HIBISCUS ...

The company's obesity drug candidate VK3019 showed stronger early weight-loss signals than Novo Nordisk’s amylin therapy. ・The company said enrollment has been completed across both Phase 3 Vanquish ...

The pharmaceutical industry has rarely seen a stock rise as spectacularly as Novo Nordisk (NVO 0.69%) did during the GLP-1 ...

Novo Nordisk has reported positive results from a clinical trial evaluating its oral semaglutide treatment in children with ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses ...

Novo Nordisk (NYSE: NVO) stock has been a trainwreck of late. In just the past 12 months, the Danish healthcare stock has lost around 60% of its value. Things have been going from bad to worse for the ...

Prothena announces Novo Nordisk obtains Fast Track Designation from the U.S. FDA for coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy ...

Obesity is not just “skin deep”; it is a chronic, complex disease. It is not a lack of willpower, a personal failure, or a ...

Health Canada approved on Tuesday the first generic version of Danish drugmaker Novo Nordisk's Ozempic drug.